Pioneering Medical Innovations
Tulavi announced an expanded indication for the allay Hydrogel Cap covering patients weighing 25 kg (55 lbs) and above, extending its reach to smaller patients at risk of symptomatic neuromas.
Axtria and Kedaara Capital completed a $240 million transaction combining secondary investment and a company-sponsored share buyback, one of the industry’s largest employee-centric liquidity events.
Positive efficacy and safety results from the pivotal SYMPHONY-PE Trial were presented at The PERT Consortium symposium and published in Circulation: Cardiovascular Interventions, with no mortality and no device-related serious adverse events.
The FDA cleared the Symphony Thrombectomy System, the first large-bore continuous vacuum system for treating pulmonary embolism.
Tulavi was selected to exhibit the allay Hydrogel Cap at the Vizient Innovative Technology Exchange in Las Vegas.
Chuck Alpuche was appointed President and Chief Operating Officer of Imperative Care.
The FDA granted premarket approval for the Embrace Hydrogel Embolic System for embolization of hypervascular tumors in peripheral arteries of 5 mm or less — the first liquid embolic approved for this indication supported by a prospective, randomized, controlled trial.
Instylla announced the appointment of Sean Boyle, who now serves as the company’s Chief Executive Officer.
Axtria was recognized in the 2025 Gartner Hype Cycle reports for Life Science Enterprise Technologies and for Healthcare and Life Science Data, Analytics, and AI.
Tulavi partnered with Veterans Healthcare Supply Solutions to distribute the allay Hydrogel Cap to VA hospitals and Military Treatment Facilities nationwide.